Answers are grounded in this paper and cite their sources.
Treatment options in multiple sclerosis (MS) have dramatically broadened over the past decade: immunomodulatory drugs, such as IFN-β and glatiramer acetate (GA), are currently applied as first-line...
No takes yet. Share an insight, caveat, or question.
Pozzilli et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: